Safimaltib
- Generic Name
- Safimaltib
A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring
Phase 1
- Conditions
- Leukemia, Myeloid, AcuteLeukemia, Lymphocytic, Chronic, B-CellLymphoma, Non-HodgkinMyelodysplastic SyndromesNeoplasmsSolid Tumor, AdultMetastatic Castration-resistant Prostate Cancer (mCRPC)
- Interventions
- First Posted Date
- 2025-01-23
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 80
- Registration Number
- NCT06788509
- Locations
- 🇨🇳
Chang Kung Memorial Hospital, Kaohsiung City, Taiwan
🇧🇪Ghent University Hospital, Gent, Belgium
🇫🇷Hopital Claude Huriez, Lille, France
A Study of the MALT1 Inhibitor JNJ-67856633 and Ibrutinib in Combination in B-cell NHL and CLL
Phase 1
Completed
- Conditions
- Leukemia, Lymphocytic, Chronic, B-CellLymphoma, Non-Hodgkin
- Interventions
- First Posted Date
- 2021-05-06
- Last Posted Date
- 2025-04-25
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 45
- Registration Number
- NCT04876092
- Locations
- 🇫🇷
Institut Paoli Calmettes, Marseille, France
🇫🇷Hopital St Louis, Paris, France
🇩🇰Rigshospitalet, Copenhagen, Denmark
A Study of JNJ-64264681 and JNJ-67856633 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
Phase 1
Completed
- Conditions
- Lymphoma, Non-HodgkinChronic Lymphocytic Leukemia
- Interventions
- First Posted Date
- 2020-12-08
- Last Posted Date
- 2025-04-25
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 75
- Registration Number
- NCT04657224
- Locations
- 🇲🇩
Arensia Exploratory Medicine, Chisinau, Moldova, Republic of
🇮🇱Hadassah Medical Center, Jerusalem, Israel
🇮🇱Sheba Medical Center, Ramat Gan, Israel
A Study of JNJ-67856633 in Participants With Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
Phase 1
Active, not recruiting
- Conditions
- Leukemia, Lymphocytic, Chronic, B-CellLymphoma, Non-Hodgkin
- Interventions
- First Posted Date
- 2019-04-03
- Last Posted Date
- 2025-04-03
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 226
- Registration Number
- NCT03900598
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸University of Nebraska Medical Center, Omaha, Nebraska, United States
🇺🇸Weill Cornell Medicine, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath